Trial Profile
A randomized Phase III pivotal trial of AT-100
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 09 Jun 2023
Price :
$35
*
At a glance
- Drugs Zelpultide alfa (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Registrational; Therapeutic Use
- Sponsors Airway Therapeutics
- 05 Jun 2023 According to an Airway Therapeutics media release, company expects to begin a Phase 3 trial by end of 2023 and which will involve at least 80 hospitals in North America and across Europe.
- 31 Mar 2022 According to an Airway Therapeutics media release, results of this trial are expected as soon as 2Q 2024.
- 30 Mar 2021 New trial record